

therefore assume that in our system the viral DNA was targeted, possibly by RdDM.

Preliminary experiments in transiently transfected plant protoplasts have also revealed that the dsRNA construct interferes with VMYMV DNA A promoter-driven expression of a reporter gene (unpublished data). This indicates that dsRNA targeting the promoter of the replicating VMYMV interferes with viral transcription. However, it cannot be excluded that dsRNA might have interfered with rolling circle replication of the virus or targeted viral single-stranded DNA. We are currently investigating the molecular mechanisms underlying the described phenomenon.

Mikhail Pooggin,
Friedrich Miescher Institute,
Maulbeerstrasse 66,
CH 4058, Basel, Switzerland
P. V. Shivaprasad and K. Veluthambi,
Department of Plant Biotechnology,
School of Biotechnology,
Madurai Kamaraj University,
Madurai 625021, India
Thomas Hohn,
Friedrich Miescher Institute,
Maulbeerstrasse 66,
CH 4058, Basel, Switzerland
(thomas.hohn@fmi.ch)

- Hannon, G.J. *Nature* **418**, 244–251 (2002).
- Smith, N.A. *et al. Nature* **407**, 319–320 (2000).
- Tenllado, F. & Diaz-Ruiz, J.R. *J. Virol* **75**, 12288–12297 (2001).
- McCaffrey, A.P. *et al. Nature* **418**, 38–39 (2002).
- Jacque, J.M., Triques, K. & Stevenson, M. *Nature* **418**, 435–438 (2002).
- Gitlin, L., Karelsky, S. & Andino, R. *Nature* **418**, 430–434 (2002).
- Mette, M.F., Aufsatz, W., van der Winden, J., Matzke, M.A. & Matzke, A.J. *EMBO J.* **19**, 5194–5201 (2000).
- Sijen, T. *et al. Curr. Biol.* **11**, 436–440 (2001).
- Jacob, S.S. *et al. Plant Dis.*, in press (2002).
- Goodall, G.J. & Filipowicz, W. *Cell* **58**, 473–483 (1989).
- Voinnet, O. & Baulcombe, D.C. *Nature* **389**, 553 (1997).

Corrections

On p. 537 of the June 2002 issue (*Nat. Biotechnol.* **20**, 527; 2002), the authors of the commentary “Liabilities and economics of transgenic crops” mistakenly reported that the European Union had banned trade in Canadian honey due to the presence of GM pollen. While there was (and continues to be) significant concern in the EU about GM pollen in both imported (and domestic) honey, the industry reports that no bans have been implemented and trade continues. Trade in honey between Canada and the EU remains based on global supply and demand conditions and is not currently impeded by government rules. The authors regret the error.

Erratum

On p. 979 of the October 2002 issue (*Nat. Biotechnol.* **20**, 979; 2002), the feature entitled “Seeking sweet relief for diabetes” incorrectly describes therapies being developed by Amylin Pharmaceuticals. Amylin has two late-stage, first-in-class diabetes drug candidates in development, SYMLIN (pramlintide acetate) and AC2993 (synthetic exendin-4). SYMLIN is a synthetic version of human amylin. SYMLIN has received an Approvable Letter from the FDA for type 1 and insulin-using type 2 diabetes. Amylin plans to submit an NDA amendment to the FDA in early 2003. Exendin-4, not amylin, is a protein found in the salivary secretions of the Gila monster and is the basis for Amylin’s second diabetes drug candidate, AC2993. AC2993 shares many of the glucose regulating attributes of GLP-1 including glucose-dependent stimulation of insulin secretion. AC2993 is currently in Phase 3, with an NDA filing planned in 2004. *Nature Biotechnology* regrets the error.

On p. 1068 of the November 2002 issue (*Nat. Biotechnol.* **20**, 1068; 2002), the Business and Regulatory News Analysis story “US panel advises resumption of gene trials,” contains an error. The “US Recombinant DNA Advisory Council” should be the “FDA Biological Response Modifiers Advisory Committee”. *Nature Biotechnology* regrets the error.

On the table of contents page of the December 2002 issue, two authors of the correspondence entitled “Expectations and reality in gene repair”, Olga Igoucheva and Vitali Alexeev, were omitted. On p. 1198 (*Nat. Biotechnol.* **20**, 1198; 2002), the text also contains an error: “In contrast, oligodeoxynucleotides exhibit a much greater gene correction rate than RDOs...” This should be replaced by “In contrast, oligodeoxynucleotides exhibit a much more consistent gene correction rate than RDOs...” *Nature Biotechnology* regrets the errors.

On p. 13 of the January 2003 issue (*Nat. Biotechnol.* **20**, 13; 2002) the commentary entitled “The sigmoidal curve of cancer”, the text in the first paragraph of column 3 contains the following erroneous text: “that, the notion that the evolution of aneuploid malignant cells is chaotic...”. The correct text is: “that the evolution of aneuploid malignant cells is chaotic...” *Nature Biotechnology* regrets this error.